P/E at 25.87 vs Industry's 34.68: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E multiple of 25.87, which is approximately 25.4% lower than the Pharmaceuticals & Biotechnology industry average of 34.68. This discount suggests that the market is pricing in either a more conservative growth outlook or risk factors relative to its peers. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, yet Dr Reddys Laboratories Ltd appears to be valued more cautiously. Investors might wonder what is the current rating? given this valuation gap and the company’s recent performance.

Performance Across Timeframes: Mixed Momentum

Examining returns over various periods reveals a complex momentum profile. Over the past year, Dr Reddys Laboratories Ltd has declined slightly by 0.70%, outperforming the Sensex’s 6.99% fall during the same period. This relative resilience contrasts with the stock’s short-term gains: a 5.43% rise over three months compared to the Sensex’s 3.04% increase, and a 4.65% gain in the past week versus the Sensex’s 1.08% loss. Year-to-date, the stock is up 4.48%, while the Sensex is down 10.44%, highlighting a divergence in momentum that favours the stock in recent months. The 1-month return of 1.60% also slightly outpaces the Sensex’s 1.20% gain. This pattern suggests a recent strengthening phase after a period of relative weakness — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Moving Average Configuration: Bullish Technical Setup

The technical picture for Dr Reddys Laboratories Ltd is notably constructive. The stock is trading above all key moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages — signalling a strong upward momentum across short, medium, and long-term horizons. This configuration is often interpreted as a bullish sign, indicating that recent gains are supported by sustained buying interest. The stock has also recorded four consecutive days of gains, accumulating a 3.68% return in this period. The proximity to its 52-week high, just 4.69% away, further underscores the strength of the current trend. Such a setup contrasts with many stocks that remain below their longer-term averages, raising the question should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Sector Performance Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently. Out of 35 stocks that have declared results, 19 reported positive outcomes, 9 were flat, and 7 posted negative results. This distribution indicates a sector with pockets of strength but also areas of caution. Dr Reddys Laboratories Ltd’s ability to outperform the Sensex over one year and maintain gains in shorter timeframes suggests it is navigating this environment relatively well. However, the sector’s elevated P/E ratio compared to the company’s valuation hints at differing growth expectations or risk assessments within the industry.

Rating Reassessment: Previously Rated Buy

On 4 May 2026, Dr Reddys Laboratories Ltd had its rating updated from a previous Buy. The Mojo Score stands at 58.0, with a current grade of Hold. This shift reflects a reassessment of the company’s fundamentals and market positioning. The rating update coincides with the valuation discount and the mixed performance signals, suggesting a more cautious stance. The interplay between valuation, momentum, and sector dynamics is critical to understanding this change — what does the current rating imply for investors?

Longer-Term Performance: Outperformance and Challenges

Looking beyond the immediate horizon, Dr Reddys Laboratories Ltd has delivered a 32.97% return over three years, outperforming the Sensex’s 21.18% gain in the same period. However, over five and ten years, the stock’s returns of 25.79% and 110.77% respectively lag behind the Sensex’s 44.82% and 189.12%. This divergence suggests that while the company has shown resilience and growth in the medium term, it has faced challenges in sustaining outperformance over longer cycles. The current valuation discount may partly reflect these historical trends and investor caution.

Intraday and Recent Trading Activity

On 24 June 2026, Dr Reddys Laboratories Ltd closed with a 2.05% gain, outperforming the sector by 0.81%. The stock opened at ₹1,314.40 and traded steadily at this level throughout the day. The consistent upward movement over the last four trading sessions, with a cumulative 3.68% gain, reinforces the positive short-term momentum. This steady performance near its 52-week high, just 4.69% shy of ₹1,376, highlights the stock’s current strength in the market.

What the Data Collectively Shows

The data on Dr Reddys Laboratories Ltd reveals a stock trading at a meaningful valuation discount relative to its sector, supported by recent positive momentum and a bullish technical setup. The company’s performance has been mixed across timeframes, with short-term gains contrasting a modest one-year decline. The sector’s mixed results and elevated P/E multiples provide context for the cautious valuation. The rating reassessment from Buy to Hold reflects this nuanced picture, balancing valuation, performance, and sector dynamics. Investors might consider whether the current rating aligns with their investment strategy in light of these factors.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →